eosinophilic esophagitis epidemiology forecast insight

DelveInsight’s ‘Eosinophilic Esophagitis – Epidemiology Forecast—2034’ report delivers an in-depth understanding of the historical and forecasted epidemiology of Eosinophilic Esophagitis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2021-2034

Eosinophilic Esophagitis: Disease Understanding

Eosinophilic Esophagitis Overview

Eosinophilic Esophagitis is a chronic, local immune-mediated esophageal disease, clinically and histologically characterized by symptoms related to esophageal dysfunction and eosinophil-predominant inflammation. The major symptoms include heartburn, regurgitation, and esophageal stenosis, and dysphagia, more frequent in young adults and children.

The disease was first described in 1978 and misinterpreted as achalasia. In the early 1980s, esophageal eosinophilia’s importance was perceived and was considered a diagnostic criterion for reflux disease. It took more than a decade before EoE was described in two case series and recognized as a distinct disease entity characterized by symptoms of esophageal dysfunction and eosinophil infiltration.

Established risk factors are male gender, Caucasian race, and atopy. Increased risk amongst family members and a single nucleotide polymorphism (SNP) in a gene coding thymic stromal lymphopoietin (TSLP) on the pseudoautosomal region of the X and Y chromosomes supports a genetic predisposition. Environmental factors including the timing and nature of food and aeroallergen exposure to the developing immune system. The pathophysiology of Eosinophilic Esophagitis is complex, with a network of various cells and molecules contributing to it, especially eosinophils, Th2 cells, TSLP, TGF-β1, and IL-13. Molecules that have not yet been identified may contribute to the mechanism of Eosinophilic Esophagitis .

The diagnosis of Eosinophilic Esophagitis depends on the clinical manifestations and endoscopic and histological findings in esophageal mucosa biopsies. Endoscopic findings in most patients include linear grooves on the esophagus wall, concentric rings, whitish exudates that resemble candidal infection, Schatzki rings, a reduction in the size of the esophagus, and superficial tears of the mucosa after endoscope introduction. A histological diagnosis is confirmed when there are ≥ 15 eosinophils per high-power field (HPF).

The Food and Drug Administration currently approves no drugs for the treatment of Eosinophilic Esophagitis . The therapeutic approach consists of the “3D” concept: diet, drugs, and dilation. The patient is treated based on the severity of their symptoms or endoscopic findings, such as esophageal narrowing or stricture. Histological improvement is usually used as the primary outcome in clinical trials rather than symptomatic improvement due to the difficulty in evaluating the symptoms objectively and uniformly. It is common for these patients to modify the patient’s dietary or eating behavior to avoid dysphagia or an impaction. PPIs are useful as a first-line treatment for patients with Eosinophilic Esophagitis . Corticosteroids are another effective therapy for the treatment of Eosinophilic Esophagitis . The formulation of the most commonly used corticosteroids, including budesonide, fluticasone propionate, and ciclesonide, influences histological remission. Esophageal endoscopic dilation is most commonly used in adults with established esophageal strictures. According to recent Eosinophilic Esophagitis consensus statements and societal guidelines, periodic dilation is now considered an acceptable alternative to medical or dietary therapy in some healthy adults with Eosinophilic Esophagitis .

Eosinophilic Esophagitis: Epidemiology

The Eosinophilic Esophagitis epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted EOE epidemiology segmented as the Diagnosed Prevalent cases of Eosinophilic Esophagitis, Gender-specific cases of Eosinophilic Esophagitis and Age-specific cases of Eosinophilic Esophagitis. The report includes the prevalent scenario of Eosinophilic Esophagitis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2021 to 2034.

Country-wise Epidemiology

The epidemiology segment also provides the Eosinophilic Esophagitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent population of Eosinophilic Esophagitis in the 7MM countries was estimated to be 547,924 cases in 2020.

As per the estimates, the United States had the highest prevalent population of Eosinophilic Esophagitis in 2020. Among the EU5 countries, Germany had the highest prevalent population of Eosinophilic Esophagitis with 39,531 cases, followed by the France in 2020. On the other hand, Spain had the lowest prevalent population of 24,612 cases in 2020.

Scope of the Report

• Eosinophilic Esophagitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.
• Eosinophilic Esophagitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Eosinophilic Esophagitis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
• The report provides insight into the historical and forecasted patient pool of Eosinophilic Esophagitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM concerning the patient population.
• The report assesses the disease risk and burden and highlights the unmet needs of Eosinophilic Esophagitis.
• The report provides the segmentation of the Eosinophilic Esophagitis epidemiology by diagnosed prevalence cases of Eosinophilic Esophagitis in the 7MM
• The report provides the segmentation of the Eosinophilic Esophagitis epidemiology by gender-specific cases of Eosinophilic Esophagitis in the 7MM.
• The report provides the segmentation of the Eosinophilic Esophagitis epidemiology by age-specific cases of Eosinophilic Esophagitis in the 7MM.

Report Highlights

• 10-year Forecast of Eosinophilic Esophagitis epidemiology
• 7MM Coverage
• Diagnosed Prevalent Cases of Eosinophilic Esophagitis
• Gender-specific Cases of Eosinophilic Esophagitis
• Age-specific Cases of Eosinophilic Esophagitis

KOL Views

We interview KOLs and obtain SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM for the patient population pertaining to Eosinophilic Esophagitis ?
• What are the key findings pertaining to the Eosinophilic Esophagitis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2021-2034)?
• What would be the total number of patients with Eosinophilic Esophagitis across the 7MM during the forecast period (2021-2034)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2021-2034)?
• At what CAGR the patient population is expected to grow by in the 7MM during the forecast period (2021-2034)?
• What are the disease risk, burdens, and unmet needs of Eosinophilic Esophagitis?
• What are the currently available treatments for Eosinophilic Esophagitis?

Reasons to buy

Eosinophilic Esophagitis Epidemiology report will allow the user to:

• Develop business strategies by understanding the trends shaping and driving the global Eosinophilic Esophagitis market
• Quantify patient populations in the global Eosinophilic Esophagitis market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Eosinophilic Esophagitis therapeutics in each of the markets covered
• Understand the magnitude of the Eosinophilic Esophagitis population by its prevalent cases.
• Understand the magnitude of the Eosinophilic Esophagitis population by its gender-specific cases.
• Understand the magnitude of the Eosinophilic Esophagitis population by its age-specific cases.
• The Eosinophilic Esophagitis epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists
• The Eosinophilic Esophagitis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over an 10-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk and Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population